share_log

Predictmedix AI Rolls Out Advanced AI-Powered Safe Entry Stations at Trinity Hospital

Predictmedix AI Rolls Out Advanced AI-Powered Safe Entry Stations at Trinity Hospital

Predictmedix AI 在三一医院推出先进的人工智能安全入口站
Accesswire ·  02/07 07:30

First deployment in Northeast India to serve as showcase for 8 Northeastern states

首次在印度东北部部署,为东北8个州提供示范

Revenue generating with potential for significant expansion

创收具有显著扩张潜力

TORONTO, ON / ACCESSWIRE / February 7, 2024 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix"), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), today announced that its state-of-the-art AI-driven Safe Entry Stations will be deployed at Trinity Hospital, Mizoram, India. This strategic initiative aims to revolutionize the screening process for vitals and mental health. Moreover, this sets the stage for broader deployment across privately held hospitals in Northeastern states. This is the company's first deployment in Northeast India which will also serve as a showcase for 8 North Eastern States in India.

安大略省多伦多/ACCESSWIRE/2024年2月7日/由专有人工智能(AI)提供支持的快速健康筛查解决方案的领先提供商Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMED)(FRA: 3QP)(“公司” 或 “Predictmedix”)今天宣布,其最先进的人工智能驱动安全入境站将部署在印度米佐拉姆三一医院。这项战略计划旨在彻底改变生命和心理健康筛查流程。此外,这为在东北各州的私营医院进行更广泛的部署奠定了基础。这是该公司在印度东北部的首次部署,也将作为印度东北8个州的展示平台。

Northeast India, encompassing eight states-Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, and Sikkim-houses a population exceeding 50 million. This region represents a significant demographic and strategic area, poised for transformative healthcare advancements and economic growth.

印度东北部包括八个州——阿鲁纳恰尔邦、阿萨姆邦、曼尼普尔邦、梅加拉亚邦、米佐拉姆邦、那加兰邦、特里普拉邦和锡金邦,人口超过5000万。该地区是一个重要的人口和战略区域,有望实现变革性的医疗保健进步和经济增长。

This deployment marks Predictmedix AI's commitment to advancing healthcare solutions by introducing cutting-edge technology to facilitate efficient and securely screening process in healthcare for vitals as well as mental health. The approach involves the implementation of AI-driven Safe Entry Stations at Trinity Hospital and a planned expansion to other privately held hospitals in Northeastern states of India, targeting improved health and safety measures.
The impact of this deployment is multifaceted, encompassing not only the generation of revenue through the implementation of Safe Entry Stations but also solidifying Predictmedix AI's position as a pivotal entity in driving transformative healthcare solutions within the region. In addition, the partnership model with Trinity Hospital, a private healthcare institution, includes a revenue-sharing agreement where 70 percent of the revenue generated from each patient screened by the AI-Powered Safe Entry Stations will be allocated to Predictmedix AI. This arrangement not only underscores the financial viability of the deployment but also highlights the potential for substantial revenue growth as the technology is adopted across additional healthcare facilities.
"We are excited to bring our AI-powered Safe Entry Stations to Trinity Hospital, enhancing their triage capabilities," commented Rahul Kushwah, COO of Predictmedix AI. " This strategic deployment not only serves the immediate needs of Trinity Hospital but also lays the groundwork for a comprehensive expansion across Northeastern India, showcasing our commitment to advancing health and safety measures.
Predictmedix AI's Safe Entry Stations utilize advanced artificial intelligence for quick and reliable health assessments, contributing to a safer and more streamlined triage process. The company looks forward to working closely with Trinity Hospital and other healthcare institutions in the region, providing innovative solutions to meet the evolving challenges in healthcare.

此次部署标志着Predictmedix AI致力于通过引入尖端技术来促进医疗保健领域高效、安全的生命和心理健康筛查流程,从而推进医疗保健解决方案的发展。该方法涉及在三一医院实施人工智能驱动的安全入境站,并计划扩展到印度东北部各州的其他私人医院,旨在改善健康和安全措施。
此次部署的影响是多方面的,不仅包括通过实施安全入境站创造收入,还巩固了Predictmedix AI作为推动该地区变革性医疗解决方案的关键实体的地位。此外,与私人医疗机构三一医院的合作模式包括一项收益分享协议,根据该协议,由人工智能驱动的安全入境站筛查的每位患者产生的收入的70%将分配给Predictmedix AI。这种安排不仅突显了部署的财务可行性,还凸显了随着该技术在其他医疗机构中得到采用,收入大幅增长的潜力。
Predictmedix AI首席运营官拉胡尔·库什瓦评论说:“我们很高兴将人工智能驱动的安全入口站引入三一医院,增强他们的分诊能力,这种战略部署不仅满足了三一医院的迫切需求,而且为印度东北部的全面扩张奠定了基础,表明了我们对推进健康和安全措施的承诺。
Predictmedix AI的安全入境站利用先进的人工智能进行快速可靠的健康评估,从而为更安全、更简化的分诊流程做出了贡献。该公司期待与三一医院和该地区的其他医疗机构密切合作,提供创新的解决方案,以应对医疗保健领域不断变化的挑战。

To receive company news, please sign up for alerts at the bottom of the page link below:

要接收公司新闻,请在页面底部注册接收提醒,链接如下:

About Predictmedix AI Inc.

关于 Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Predictmedix AI Inc.(CSE:PMED)(场外交易代码:PMEDF)(FRA: 3QP)是全球快速健康筛查和远程患者护理解决方案的新兴提供商。该公司的安全入境站由专有的人工智能(AI)提供支持,使用多光谱摄像机分析生理数据模式并预测各种健康问题,包括19种生理生命参数、药物或酒精损害、疲劳或各种精神疾病。Predictmedix AI 专有的远程患者护理平台为医疗专业人员提供了一套人工智能驱动的工具,以改善患者的健康状况。要了解更多信息,请访问我们的网站或在推特、Instagram或领英上关注我们。

Public Relations Contact

公共关系联系人

For further media information or to set up an interview, please contact:

欲了解更多媒体信息或安排采访,请联系:

Nelson Hudes

纳尔逊·哈德斯

Communications International (905) 660 9155

通信国际 (905) 660 9155

Nelson@hudescommunications.com

Nelson@hudescommunications.com

Dr. Rahul Kushwah (647) 889 6916

Rahul Kushwah 博士 (647) 889 6916

Caution Regarding Forward-Looking Information:

关于前瞻性信息的注意事项:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

本新闻稿可能包含前瞻性陈述和基于当前预期的信息。这些陈述不应被视为对公司未来业绩或业绩的保证。此类陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致实际业绩、业绩或成就与此类陈述所暗示的结果存在重大差异。尽管此类陈述基于管理层的合理假设,但无法保证此类假设会被证明是正确的。我们不负责更新或修改它们以反映新的事件或情况。公司的证券尚未根据经修订的1933年《美国证券法》(“美国证券法”)或适用的州证券法进行注册,如果没有注册或不受此类注册要求的适用豁免,则不得向在美国的人或 “美国个人”(该术语的定义见美国证券法的法规)发行或出售,也不得为他们的账户或利益发行或出售。本新闻稿不构成出售要约或招揽买入要约,也不得在美国或任何此类要约、招揽或出售非法的司法管辖区出售证券。此外,还有一些已知和未知的风险因素可能导致公司的实际业绩、业绩或成就与本文件所含前瞻性信息所表达或暗示的未来业绩、业绩或成就存在重大差异,例如但不限于依赖获得监管部门批准;获得与其技术相关的知识产权的能力;运营历史有限;一般商业、经济、竞争、政治、监管和社会不确定性,以及特别是与 COVID-19 相关的不确定性;与公司无法控制的因素相关的风险,包括与 COVID-19 相关的风险;与公司股票相关的风险,包括该方可能也可能无法控制的事件导致的价格波动;对管理层的依赖;以及该行业其他竞争对手的紧急情况。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

本文中的所有前瞻性信息均受本警示声明的全面限制,除非法律要求,否则公司不承担任何修改或更新任何此类前瞻性信息或公开宣布为反映未来业绩、事件或发展而对本文包含的任何前瞻性信息进行任何修订的结果的义务。

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

免责声明:“公司目前并未明确或暗示其产品有能力诊断、消除、治愈或遏制 COVID-19(或 SARS-2 冠状病毒)。

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所尚未审查本新闻稿的充分性或准确性,也不承担任何责任。

SOURCE: Predictmedix AI Inc.

来源:Predictmedix AI Inc.


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发